How Xolair Targets Food Allergies
Xolair (omalizumab) treats food allergies by blocking immunoglobulin E (IgE), the antibody that triggers allergic reactions. In people with IgE-mediated food allergies, exposure to allergens like peanuts or milk binds to IgE on mast cells and basophils, causing rapid release of histamine and other chemicals that lead to symptoms from hives to anaphylaxis. Xolair binds free IgE before it attaches to these cells, reducing overall IgE levels and preventing the cascade.[1][2]
Clinical trials showed it allows patients to tolerate higher doses of allergens without severe reactions. In the OUtMATCH study, kids and teens on Xolair could eat about 2.5 times more peanut protein than placebo groups during supervised challenges, with 67% tolerating at least 600 mg (roughly three peanuts).[3]
Who Qualifies for Xolair in Food Allergies
FDA approved Xolair in 2024 for reducing allergic reactions in people ages 1+ with IgE-mediated allergies to cashew, milk, egg, peanut, walnut, hazelnut, or wheat after accidental exposure. It requires confirmed allergy via skin or blood tests, IgE levels ≤700 IU/mL, and body weight ≤150 kg. It's not for severe past anaphylaxis needing intubation or for those with certain uncontrolled conditions.[1][4]
How It's Administered and How Long Treatment Lasts
Patients get subcutaneous injections every 2-4 weeks, dosed by weight and IgE level (75-600 mg per dose). Treatment starts 16-20 weeks before oral immunotherapy (OIT), continues through desensitization, and extends 8 more weeks post-OIT. Long-term use may be needed to maintain benefits, as effects wane without it.[1][2]
What Happens During Oral Immunotherapy with Xolair
Xolair pairs with OIT, where patients consume increasing allergen doses under medical supervision to build tolerance. Xolair lowers reaction risk during this buildup—trial data showed reaction rates dropped 73% vs. placebo. It doesn't cure allergies; patients must still avoid triggers and carry epinephrine.[3][5]
Common Side Effects and Risks
Injection-site reactions, fever, and joint pain occur in >40% of users. Anaphylaxis risk exists (0.1% per dose), so first doses happen in a healthcare setting with 30-minute monitoring. During OIT, 17% had severe reactions vs. 7% on placebo. Eosinophilic esophagitis affected 9% in trials. Long-term safety data is limited.[1][3]
Does Xolair Work for All Food Allergies?
No—only FDA-approved for specific tree nuts, peanut, milk, egg, and wheat. Efficacy varies by allergen; peanut and tree nuts showed strongest data. It's ineffective for non-IgE allergies like oral allergy syndrome. Patents protect it until at least 2030 in the US, with no generics yet.[1][6]
Sources
[1]: Xolair Prescribing Information (FDA)
[2]: NEJM: Omalizumab for IgE-Mediated Food Allergy
[3]: FDA Approval Summary for Xolair in Food Allergy
[4]: AAAAI Guidelines on Xolair for Food Allergy
[5]: NIAID-Sponsored OUtMATCH Study Results
[6]: DrugPatentWatch: Xolair Patents